See the DrugPatentWatch profile for keytruda

Comparing the Cost of Keytruda to Similar Immunotherapies: A Breakdown

Immunotherapy has revolutionized the treatment of various types of cancer, offering patients a new hope for survival. Among the many immunotherapies available, Keytruda (pembrolizumab) has emerged as a leading treatment option for several types of cancer, including melanoma, lung cancer, and head and neck cancer. However, the high cost of Keytruda has raised concerns among patients, healthcare providers, and payers. In this article, we'll delve into the cost of Keytruda and compare it to similar immunotherapies.

What is Keytruda?

Keytruda is a programmed death receptor-1 (PD-1) inhibitor, a type of immunotherapy that works by blocking the PD-1 protein on T-cells, allowing them to recognize and attack cancer cells more effectively. It was approved by the FDA in 2014 for the treatment of advanced melanoma and has since been approved for several other types of cancer.

Cost of Keytruda

The cost of Keytruda varies depending on the dosage and treatment duration. According to the manufacturer, Merck, the average wholesale price (AWP) of Keytruda is around $12,500 per month. However, the actual cost to patients and payers can be significantly higher due to various factors, including administration costs, hospital stays, and other related expenses.

Comparing the Cost of Keytruda to Similar Immunotherapies

Several other immunotherapies are available for the treatment of various types of cancer. Let's compare the cost of Keytruda to some of these similar immunotherapies:

Opdivo (nivolumab)

Opdivo is another PD-1 inhibitor approved for the treatment of various types of cancer, including melanoma, lung cancer, and kidney cancer. According to DrugPatentWatch.com, the average wholesale price of Opdivo is around $10,000 per month.

Yervoy (ipilimumab)

Yervoy is a CTLA-4 inhibitor, another type of immunotherapy that works by blocking the CTLA-4 protein on T-cells. It is approved for the treatment of melanoma and is often used in combination with other immunotherapies. According to the manufacturer, Bristol-Myers Squibb, the average wholesale price of Yervoy is around $10,000 per month.

Bavencio (avelumab)

Bavencio is a PD-L1 inhibitor approved for the treatment of Merkel cell carcinoma and urothelial carcinoma. According to the manufacturer, EMD Serono, the average wholesale price of Bavencio is around $12,000 per month.

Tecentriq (atezolizumab)

Tecentriq is a PD-L1 inhibitor approved for the treatment of various types of cancer, including lung cancer, breast cancer, and urothelial carcinoma. According to the manufacturer, Genentech, the average wholesale price of Tecentriq is around $10,000 per month.

Conclusion

Keytruda is a highly effective immunotherapy for the treatment of various types of cancer, but its high cost has raised concerns among patients, healthcare providers, and payers. While it is more expensive than some of its competitors, such as Opdivo and Yervoy, it is also more effective in some cases. As the cost of healthcare continues to rise, it is essential to consider the cost-effectiveness of immunotherapies like Keytruda and to explore ways to make them more affordable for patients.

Frequently Asked Questions

1. What is the average wholesale price of Keytruda?
The average wholesale price of Keytruda is around $12,500 per month.

2. How does the cost of Keytruda compare to other immunotherapies?
The cost of Keytruda is higher than some of its competitors, such as Opdivo and Yervoy, but it is also more effective in some cases.

3. What is the average wholesale price of Opdivo?
The average wholesale price of Opdivo is around $10,000 per month.

4. How does the cost of Keytruda affect patients?
The high cost of Keytruda can be a significant burden for patients, who may have to pay out-of-pocket for their treatment or navigate complex insurance coverage.

5. Are there any ways to make Keytruda more affordable for patients?
Yes, there are several ways to make Keytruda more affordable for patients, including patient assistance programs, copay cards, and generic alternatives.

Sources:

1. Merck. (2022). Keytruda (pembrolizumab) Prescribing Information.
2. Bristol-Myers Squibb. (2022). Yervoy (ipilimumab) Prescribing Information.
3. EMD Serono. (2022). Bavencio (avelumab) Prescribing Information.
4. Genentech. (2022). Tecentriq (atezolizumab) Prescribing Information.
5. DrugPatentWatch.com. (2022). Average Wholesale Prices for Keytruda, Opdivo, and Yervoy.